Cargando…
Coexistent ARID1A-PIK3CA mutations are associated with immune-related pathways in luminal breast cancer
Up to 40% of luminal breast cancer patients carry activating mutations in the PIK3CA gene. PIK3CA mutations commonly co-occur with other mutations, but the implication of this co-occurrence may vary according to the specific genes involved. Here, we characterized a subgroup of luminal breast cancer...
Autores principales: | Anabel Sinberger, Liat, Zahavi, Tamar, Sonnenblick, Amir, Salmon‐Divon, Mali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684499/ https://www.ncbi.nlm.nih.gov/pubmed/38017109 http://dx.doi.org/10.1038/s41598-023-48002-x |
Ejemplares similares
-
Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment
por: Raphael, Ari, et al.
Publicado: (2022) -
Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors
por: Feldman, Didi, et al.
Publicado: (2023) -
SYK expression level distinguishes control from BRCA1-mutated lymphocytes
por: Zahavi, Tamar, et al.
Publicado: (2018) -
Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model
por: Zahavi, Tamar, et al.
Publicado: (2015) -
pAKT pathway activation is associated with PIK3CA mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activation
por: Sonnenblick, Amir, et al.
Publicado: (2019)